to join the discussion
Clicks has built a formidable retail footprint in pharmacy and health, but I'm more intrigued by how the group navigates margin compression from generic competition and rising input costs over the next 18-24 months. The distribution network is genuinely valuable, yet I'd need to
The market's flat reaction to CLS at R26275 misses a critical supply chain reality: inventory turnover metrics at retail partners have tightened considerably, suggesting margin compression is overstated in current valuations. My logistics checks across distribution hubs show phar
Clicks at R26686 is interesting for the long term since people will always need their products and pharmacies aren't going anywhere, but I'm wondering if the price will keep climbing or if I should wait for a better entry point since it's just up a tiny bit today?
With CLS down 0.72% today while the rand weakens against the dollar, I'm curious whether the market is undervaluing the rand-hedge benefit here. The pharmacy retail exposure is domestic-facing, but how much does FX headwind pricing power offset the currency tailwind when you look
Clicks down 58 basis points today is noise in a defensive retail play, but with consumer spending under pressure and margin compression across the sector, I'm not convinced the pullback presents genuine value unless we see evidence of inventory normalisation and fuel cost relief
CLS up 1.40% to R30238 today but the real question is whether retail margins hold up if consumer spending stays under pressure. Clicks has pricing power but not infinite room.
CLS at R30197 climbing 1.26% today, but the real question is whether their pharmacy network can defend margins as private healthcare costs soar and generics squeeze retail. They've got scale that matters, yet I'm seeing margin compression risk that the market hasn't fully priced
CLS at R30090 gaining 0.91% while Dis-Chem stumbles tells me retailers are bifurcating. Clicks' logistics grip is just cleaner than competitors right now.
CLS at R30k is still expensive for a business dealing with margin compression in pharmacy retail, but the network moat keeps it defensible long-term. Wonder if they've done enough to move beyond the till and actually compete in health tech.
Up nearly 1% today but CLS is still pricing in recession fears that don't match their pricing power in pharma. That 0.98% bounce feels like profit-taking before the real rebound.
CLS down 0.42% to R29,889 — retail headwinds biting harder than expected, or just profit-taking after the recent run?
Clicks Group on my watchlist. CLS results season will be the real test.
Clicks Group — the balance sheet looks cleaner than the share price suggests. CLS at R29061.00.
CLS up 0.93% but that R29.5k price tag feels stretched given pharmacy margin compression. Where's the growth narrative beyond same-store sales?
CLS creeping up 0.92% today but that's still just noise when you're sitting at R29k. Is the pharmacy resilience story actually working or are we just seeing retail ETF flows?
CLS down 0.94% to R28914 — pharmacy margins getting squeezed by generics, but the beauty side still printing cash. Question is whether Same-store Sales growth can offset that pressure.
CLS up 1.51% to R29,641 while Dis-Chem trades sideways—healthcare retail divergence is wild. Clicks' resilience in pharma outpacing Dis-Chem's drag from beauty/wellness exposure.
Up 1.51% on what exactly? Clicks' margin pressure is real and today's pop feels like retail FOMO ahead of earnings. That R296 level won't hold if same-store sales disappoint.
CLS up 0.84% to R29445 while Dis-Chem's been getting hammered on margin pressure. Clicks' defensive model holding up better, but that valuation's getting stretched versus the pharmacy peers.
CLS up 0.95% to R29,478 but retail pharmacy margins are getting squeezed harder than ever. Their pharmacy business can't offset the beauty/health downtrend forever.